Sees FY25 revenue $729M-$737M, consensus $727.5M
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen reports Q3 adjusted EPS 46c, consensus 42c
- Is RGEN a Buy, Before Earnings?
- Novo Nordisk update raises questions on Repligen approval, says Canaccord
- Repligen price target raised to $160 from $150 at Barclays
- Repligen’s Growth Potential: A Buy Rating Backed by Innovation and Strategic Positioning